<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Spruce Biosciences, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/spruce-biosciences-inc-1</link>
    <description>Latest news and press releases for Spruce Biosciences, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 20 Apr 2026 20:01:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/spruce-biosciences-inc-1" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7869c51cc36e475343873.webp</url>
      <title>Spruce Biosciences, Inc.</title>
      <link>https://6ix.com/company/spruce-biosciences-inc-1</link>
    </image>
    <item>
      <title>Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants</title>
      <link>https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants</link>
      <guid isPermaLink="true">https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants</guid>
      <pubDate>Mon, 20 Apr 2026 20:01:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., April 20, 2026--Spruce Biosciences, Inc. (&quot;Spruce Biosciences&quot;) (NASDAQ: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has commenced an underwritten public offering of shares of its common stock or pre-funded warrants to purchase shares of its common stock in lieu thereof. All of the securities are being offered by Spruce B</description>
    </item>
    <item>
      <title>Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer</title>
      <link>https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-appoints-dale-hooks-an-accomplished-rare-disease-commercial-leader-as-chief-commercial-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-appoints-dale-hooks-an-accomplished-rare-disease-commercial-leader-as-chief-commercial-officer</guid>
      <pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
      <description>Mr. Hooks Brings Over Three Decades of Comprehensive Biopharmaceutical Marketing and Commercialization Expertise, Including the Launch of 21 New Products</description>
    </item>
    <item>
      <title>Spruce Biosciences to Present at Upcoming Investor Conferences in March</title>
      <link>https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-to-present-at-upcoming-investor-conferences-in-march</link>
      <guid isPermaLink="true">https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-to-present-at-upcoming-investor-conferences-in-march</guid>
      <pubDate>Mon, 02 Mar 2026 21:05:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., March 02, 2026--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at two upcoming investor conferences taking place in March.</description>
    </item>
    <item>
      <title>Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)</title>
      <link>https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-announces-positive-type-b-meetings-with-us-fda-for-ta-ert-for-the-treatment-of-sanfilippo-syndrome-type-b-mps-iiib</link>
      <guid isPermaLink="true">https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-announces-positive-type-b-meetings-with-us-fda-for-ta-ert-for-the-treatment-of-sanfilippo-syndrome-type-b-mps-iiib</guid>
      <pubDate>Wed, 18 Feb 2026 05:00:00 GMT</pubDate>
      <description>Based on FDA Feedback, Company Continues to Advance BLA Submission for TA-ERT Using CSF HS-NRE as Reasonably Likely Surrogate Endpoint for Accelerated</description>
    </item>
    <item>
      <title>Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
      <link>https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-to-participate-in-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-to-participate-in-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</guid>
      <pubDate>Tue, 17 Feb 2026 21:05:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., February 17, 2026--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 3:20 p.m. ET.</description>
    </item>
    <item>
      <title>Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team</title>
      <link>https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-adds-regulatory-and-clinical-development-expertise-to-leadership-team</link>
      <guid isPermaLink="true">https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-adds-regulatory-and-clinical-development-expertise-to-leadership-team</guid>
      <pubDate>Tue, 03 Feb 2026 05:00:00 GMT</pubDate>
      <description>Daven Mody, Pharm.D., Appointed as Senior Vice President, Regulatory and Quality Bruno Gagnon, B.Pharm., M.Sc., Appointed as Senior Vice President, Clinical</description>
    </item>
    <item>
      <title>Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™</title>
      <link>https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-announces-data-presentations-at-the-22nd-annual-worldsymposiumtm</link>
      <guid isPermaLink="true">https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-announces-data-presentations-at-the-22nd-annual-worldsymposiumtm</guid>
      <pubDate>Wed, 28 Jan 2026 05:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and</description>
    </item>
    <item>
      <title>Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration</title>
      <link>https://6ix.com/company/spruce-biosciences-inc-1/news/harbour-biomed-acquires-common-stock-in-spruce-biosciences-deepening-strategic-collaboration-1</link>
      <guid isPermaLink="true">https://6ix.com/company/spruce-biosciences-inc-1/news/harbour-biomed-acquires-common-stock-in-spruce-biosciences-deepening-strategic-collaboration-1</guid>
      <pubDate>Mon, 19 Jan 2026 00:02:00 GMT</pubDate>
      <description>Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (Nasdaq: SPRB) (&quot;Spruce&quot;). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of</description>
    </item>
    <item>
      <title>Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital</title>
      <link>https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-secures-up-to-dollar50-million-in-growth-capital-from-avenue-capital</link>
      <guid isPermaLink="true">https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-secures-up-to-dollar50-million-in-growth-capital-from-avenue-capital</guid>
      <pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., January 08, 2026--Spruce Biosciences, Inc. (Spruce) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that, on January 7, 2026, it entered into a loan facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group (Avenue Capital), for up to $50 million in growth capital.</description>
    </item>
    <item>
      <title>Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors</title>
      <link>https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-appoints-proven-pharmaceutical-commercial-leader-keli-walbert-to-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-appoints-proven-pharmaceutical-commercial-leader-keli-walbert-to-board-of-directors</guid>
      <pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
      <description>Keli Walbert brings decades of commercial leadership experience and a proven track record of successful product launches in rare disease SOUTH SAN FRANCISCO,</description>
    </item>
    <item>
      <title>Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates</title>
      <link>https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-reports-third-quarter-2025-financial-results-and-provides-corporate-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-reports-third-quarter-2025-financial-results-and-provides-corporate-updates</guid>
      <pubDate>Mon, 10 Nov 2025 21:05:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., November 10, 2025--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2025 and provided corporate updates.</description>
    </item>
    <item>
      <title>Spruce Biosciences Announces $50.0 Million Private Placement Financing</title>
      <link>https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-announces-dollar500-million-private-placement-financing</link>
      <guid isPermaLink="true">https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-announces-dollar500-million-private-placement-financing</guid>
      <pubDate>Wed, 08 Oct 2025 04:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and</description>
    </item>
    <item>
      <title>Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)</title>
      <link>https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-receives-us-fda-breakthrough-therapy-designation-for-tralesinidase-alfa-enzyme-replacement-therapy-ta-ert-in-sanfilippo-syndrome-type-b-mps-iiib</link>
      <guid isPermaLink="true">https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-receives-us-fda-breakthrough-therapy-designation-for-tralesinidase-alfa-enzyme-replacement-therapy-ta-ert-in-sanfilippo-syndrome-type-b-mps-iiib</guid>
      <pubDate>Mon, 06 Oct 2025 04:00:00 GMT</pubDate>
      <description>Breakthrough Therapy Designation Supported by Integrated Long-Term Clinical Data Demonstrating Normalization in Cerebral Spinal Fluid Heparan Sulfate</description>
    </item>
    <item>
      <title>Spruce Biosciences Resumes Trading on the Nasdaq Capital Market</title>
      <link>https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-resumes-trading-on-the-nasdaq-capital-market-1</link>
      <guid isPermaLink="true">https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-resumes-trading-on-the-nasdaq-capital-market-1</guid>
      <pubDate>Mon, 15 Sep 2025 11:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., September 15, 2025--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that it will resume trading on the Nasdaq Capital Market at the market open today, September 15, 2025, under the ticker symbol &quot;SPRB&quot; and CUSIP 85209E 208.</description>
    </item>
    <item>
      <title>Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)</title>
      <link>https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-announces-integrated-long-term-clinical-data-of-tralesinidase-alfa-enzyme-replacement-therapy-ta-ert-demonstrating-profound-and-durable-efficacy-and-safety-in-patients-with-sanfilippo-syndrome-type-b-mps-iiib</link>
      <guid isPermaLink="true">https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-announces-integrated-long-term-clinical-data-of-tralesinidase-alfa-enzyme-replacement-therapy-ta-ert-demonstrating-profound-and-durable-efficacy-and-safety-in-patients-with-sanfilippo-syndrome-type-b-mps-iiib</guid>
      <pubDate>Thu, 14 Aug 2025 04:00:00 GMT</pubDate>
      <description>TA-ERT Profoundly and Durably Lowered Cerebral Spinal Fluid Heparan Sulfate Non-Reducing End (CSF HS-NRE), the Factor Responsible for Neurodegeneration in</description>
    </item>
    <item>
      <title>Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates</title>
      <link>https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-reports-second-quarter-2025-financial-results-and-provides-corporate-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-reports-second-quarter-2025-financial-results-and-provides-corporate-updates</guid>
      <pubDate>Thu, 14 Aug 2025 04:00:00 GMT</pubDate>
      <description>Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrates Profound and Durable Efficacy and Safety in</description>
    </item>
    <item>
      <title>Spruce Biosciences Announces Reverse Stock Split</title>
      <link>https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-announces-reverse-stock-split-1</link>
      <guid isPermaLink="true">https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-announces-reverse-stock-split-1</guid>
      <pubDate>Thu, 24 Jul 2025 04:00:00 GMT</pubDate>
      <description>Spruce’s Common Stock to Begin Trading on a Post-Split Adjusted Basis on August 5, 2025 Relisting on Nasdaq Capital Market Anticipated Following Compliance</description>
    </item>
    <item>
      <title>HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder</title>
      <link>https://6ix.com/company/spruce-biosciences-inc-1/news/hmnc-brain-health-and-spruce-biosciences-announce-first-patient-dosed-in-phase-2-tamarind-trial-for-major-depressive-disorder-1</link>
      <guid isPermaLink="true">https://6ix.com/company/spruce-biosciences-inc-1/news/hmnc-brain-health-and-spruce-biosciences-announce-first-patient-dosed-in-phase-2-tamarind-trial-for-major-depressive-disorder-1</guid>
      <pubDate>Tue, 22 Jul 2025 14:31:00 GMT</pubDate>
      <description>Study Initiation Marks Key Milestone in Advancing Precision Psychiatry Treatment for Major Depressive Disorder Topline Results Anticipated in the First Half of 2026 MUNICH, Germany and SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC”), a global precision psychiatry biopharmaceutical company, in collaboration with Spruce Biosciences, Inc. (OTCQB: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapi</description>
    </item>
    <item>
      <title>Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market</title>
      <link>https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-announces-conditional-nasdaq-approval-to-resume-trading-on-the-nasdaq-capital-market-1</link>
      <guid isPermaLink="true">https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-announces-conditional-nasdaq-approval-to-resume-trading-on-the-nasdaq-capital-market-1</guid>
      <pubDate>Thu, 12 Jun 2025 04:00:00 GMT</pubDate>
      <description>Relisting Contingent Upon Stockholder Approval of Reverse Stock Split Trading on Nasdaq Capital Market Anticipated to Commence On or Before August 5, 2025</description>
    </item>
    <item>
      <title>Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates</title>
      <link>https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-reports-first-quarter-2025-financial-results-and-provides-corporate-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/spruce-biosciences-inc-1/news/spruce-biosciences-reports-first-quarter-2025-financial-results-and-provides-corporate-updates</guid>
      <pubDate>Tue, 06 May 2025 20:01:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., May 06, 2025--Spruce Biosciences, Inc. (OTC: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2025 and provided corporate updates.</description>
    </item>
  </channel>
</rss>